Clinical Research Trials on Liver Cancer

The physicians and health care team at the UPMC Liver Cancer Center are engaged in clinical research trials to determine the latest state-of-the-art treatment for liver tumors.

For more information about clinical research at the UPMC Liver Cancer Center, please contact us.

Active Clinical Research Protocols

Study Title

Light Therapy in Patients Undergoing Hepatectomy

Purpose

To determine if Blue Light Therapy improves patient outcomes following major liver resection.

Principal Investigator

Allan Tsung, MD, FACS

Study Title

Palliative Care Intervention for Socioeconomically Disadvantaged Advanced Cancer Patients

Purpose

To test the efficacy of a collaborative care intervention to reduce symptoms of pain, depression, and fatigue in patients diagnosed with cancer. The study will also assess the predictors of caregiving on cardiovascular risk.

Principal Investigator

Jennifer Steel, PhD

Study Title

Caregiver-guided Pain Management Training in Pallatative Care

Purpose

To test the efficacy of a caregiver guided pain management intervention to reduce pain in advanced cancer patients and improve adjustment in caregivers.

Principal Investigator

Jennifer Steel, PhD​

Study Title

Investigation of Serum and Tissue Markers as Predictors for Survival and Response to Therapy and Development of Biomarkers for Liver and Biliary Disease

Purpose

To facilitate research involving hepatobiliary diseases and promote multidisciplinary collaborative research projects. Learn more about this study.

Principal Investigator

Allan Tsung, MD, FACS​

Upcoming Clinical Research Protocols

Study Title​

Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery

Purpose​​

To test the technical feasibility of multimodality image fusion and visualization for guiding laparoscopic liver surgery.


Study Title

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination with Systemic Pembrolizumab

Purpose

To evaluate the safety and efficacy of talimogene laherparepvec, injected intrahepatically, into tumors with known progression alone and in combination with systemic IV administration of pembrolizumab in subjects with HCC.

Clinical Research Interests

  • Gene therapy trials for primary and metastatic liver cancer
  • Augmented liver reality imaging to enhance laparoscopic liver surgery and ablation
  • Human hepatocyte isolation to study I/R injury and cancer signaling pathways
  • CyberKnife® treatment and follow-up for primary or metastatic liver tumors
  • A Phase II study of yttrium-90 microspheres (SIR-Spheres®) therapy for the treatment of unresectable hepatocellular carcinoma (HCC)
  • Regional therapy with transarterial chemoembolization (TACE) vs. SIR-Spheres® for liver metastases secondary to neuroendocrine tumors
  • Cold vs. warm ischemia and other factors that influence cell viability, morphology, and function in hepatocytes

Recent Clinical Research Protocols

  • NSABP PROTOCOL C-11: A Phase III, multicenter, randomized trial that will evaluate the difference in recurrence-free survival between patients with resectable hepatic colorectal metastases receiving perioperative (preoperative plus postoperative) chemotherapy and those receiving only postoperative chemotherapy following hepatic surgery to resect colorectal metastases.
  • BTG (STOP-HCC) Trial: To evaluate TheraSphere® in the treatment of patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib therapy is planned.
  • NSABP PROTOCOL FC-6: A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 Plus Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer with Metastases Confined to the Liver
  • LC® Drug Eluting Bead for Regional Chemoembolization to Downstage or Bridge Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation
  • Phase I/II Trial Testing Immunization with AFP Plus GM-CSF Plasmid and AFP Adenoviral Vector Boost in Patients with Hepatocellular Carcinoma (HCC)
  • Computer-Mediated Strategies for Symptom Management
  • Analysis of the Cytokine-Immunological Model of Cancer

For more information about active clinical research, interests, or protocols at the UPMC Liver Cancer Center, please contact us.​​​​​​​​

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences | Supplemental content provided by Healthwise, Incorporated. To learn more, visit www.healthwise.org

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

UPMC
Pittsburgh, PA, USA | UPMC.com